Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
S Afr Med J ; 111(3): 227-233, 2021 03 02.
Article in English | MEDLINE | ID: mdl-33944744

ABSTRACT

BACKGROUND: Evidence on mask use in the general population is needed to inform SARS-CoV-2 responses. OBJECTIVES: To assess the effectiveness of cloth and medical masks for preventing SARS-CoV-2 transmission in community settings. METHODS: Two rapid reviews were conducted searching three electronic databases (PubMed, Embase, Cochrane Library) and two clinical trials registries on 30 and 31 March 2020. RESULTS: We screened 821 records and assessed nine full-text articles for eligibility. One and seven RCTs were included for cloth and medical mask reviews, respectively. No SARS-CoV-2-specific RCTs and no cloth mask RCTs in community settings were identified. A single hospital-based RCT provided indirect evidence that, compared with medical masks, cloth masks probably increase clinical respiratory illnesses (relative risk (RR) 1.56; 95% confidence interval (CI) 0.98 - 2.49) and laboratory-confirmed respiratory virus infections (RR 1.54; 95% CI 0.88 - 2.70). Evidence for influenza-like illnesses (ILI) was uncertain (RR 13.00; 95% CI 1.69 - 100.03). Two RCTs provide low-certainty evidence that medical masks may make little to no difference to ILI infection risk versus no masks (RR 0.98; 95% CI 0.81 - 1.19) in the community setting. Five RCTs provide low-certainty evidence that medical masks may slightly reduce infection risk v. no masks (RR 0.81; 95% CI 0.55 - 1.20) in the household setting. CONCLUSIONS: Direct evidence for cloth and medical mask efficacy and effectiveness in the community is limited. Decision-making for mask use may consider other factors such as feasibility and SARS-CoV-2 transmission dynamics; however, well-designed comparative effectiveness studies are required.


Subject(s)
COVID-19/prevention & control , Infection Control/methods , Masks , Pneumonia, Viral/prevention & control , Humans , Influenza, Human/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/virology , SARS-CoV-2 , Textiles
2.
S Afr Med J ; 109(11b): 77-82, 2019 Dec 05.
Article in English | MEDLINE | ID: mdl-32252873

ABSTRACT

Over the past three decades, tremendous global progress in preventing and treating paediatric HIV infection has been achieved. This paper highlights the emerging health challenges of HIV-exposed uninfected (HEU) children and the ageing population of children living with HIV (CLHIV), summarises programmatic opportunities for care, and highlights currently conducted research and remaining research priorities in high HIV-prevalence settings such as South Africa. Emerging health challenges amongst HEU children and CLHIV include preterm delivery, suboptimal growth, neurodevelopmental delay, mental health challenges, infectious disease morbidity and mortality, and acute and chronic respiratory illnesses including tuberculosis, pneumonia, bronchiectasis and lymphocytic interstitial pneumonitis. CLHIV and HEU children require three different categories of care: (i) optimal routine child health services applicable to all children; (ii) routine care currently provided to all HEU children and CLHIV, such as HIV testing or viral load monitoring, respectively, and (iii) additional care for CLHIV and HEU children who may have growth, neurodevelopmental, behavioural, cognitive or other deficits such as chronic lung disease, and require varying degrees of specialised care. However, the translation thereof into practice has been hampered by various systemic challenges, including shortages of trained healthcare staff, suboptimal use of the patient-held child's Road to Health book for screening and referral purposes, inadequate numbers and distribution of therapeutic staff, and shortages of assistive/diagnostic devices, where required. Additionally, in low-middle-income high HIV-prevalence settings, there is a lack of evidence-based solutions/models of care to optimise health amongst HEU and CLHIV. Current research priorities include understanding the mechanisms of preterm birth in women living with HIV to optimise preventive interventions; establishing pregnancy pharmacovigilance systems to understand the short-, medium- and long-term impact of in utero ART and HIV exposure; understanding the role of preconception maternal ART on HEU child infectious morbidity and long-term growth and neurodevelopmental trajectories in HEU children and CLHIV, understanding mental health outcomes and support required in HEU children and CLHIV through childhood and adolescence; monitoring HEU child morbidity and mortality compared with HIV-unexposed children; monitoring outcomes of CLHIV who initiated ART very early in life, sometimes with suboptimal ART regimens owing to medication formulation and registration issues; and testing sustainable models of care for HEU children and CLHIV including later reproductive care and support.


Subject(s)
Anti-HIV Agents/therapeutic use , Child Development , HIV Infections/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Mental Health , Pregnancy Complications, Infectious/drug therapy , Prenatal Exposure Delayed Effects , Adolescent , Child , Child Health Services , Child, Preschool , Chronic Disease , Educational Status , Female , Fetal Growth Retardation , HIV Infections/diagnosis , HIV Infections/drug therapy , HIV Infections/transmission , Humans , Infant , Infant, Newborn , Pregnancy , Premature Birth , Research , Respiratory Tract Diseases
3.
S Afr Med J ; 109(11b): 83-88, 2019 Dec 05.
Article in English | MEDLINE | ID: mdl-32252874

ABSTRACT

Although the neonatal mortality rate in South Africa (SA) has remained stagnant at 12 deaths per 1 000 live births, the infant and under-5 mortality rates have significantly declined since peaking in 2003. Policy changes that have influenced this decline include policies to prevent vertical HIV transmission, earlier treatment of children living with HIV, expanded immunisation policies, strengthening breastfeeding practices, and health policies to contain tobacco and sugar use. The Sustainable Development Goals (2016 - 2030) have shifted the focus from keeping children alive, as expressed in the Millennium Development Goals (1990 - 2015), to achieving optimal health through the 'Survive, thrive and transform' global agenda. This paper focuses on important remaining causes of childhood mortality and morbidity in SA, specifically respiratory illness, environmental pollution, tuberculosis, malnutrition and vaccine-preventable conditions. The monitoring of maternal and child health (MCH) outcomes is crucial, and has improved in SA through both the District Health Information and Civil Registration and Vital Statistics systems, although gaps remain. Intermittent surveys and research augment the routinely collected data. However, availability and use of local data to inform quality and effectiveness of care is critical, and this requires ownership at the collection point to facilitate local redress. Potential game changers to improve MCH outcomes include mobile health and community-based interventions. In SA, improved MCH remains a crucial factor for human capital development. There is a pressing need to focus beyond childhood mortality and to ensure that each child thrives.


Subject(s)
Child Health , Health Policy , Infant Health , Anti-HIV Agents/therapeutic use , Breast Feeding , Child Mortality , Child Nutrition Disorders/epidemiology , Child Nutrition Disorders/mortality , Child Nutrition Disorders/prevention & control , Child, Preschool , Environmental Pollution/prevention & control , Environmental Pollution/statistics & numerical data , Female , HIV Infections/prevention & control , HIV Infections/transmission , Humans , Infant , Infant Formula , Infant Mortality , Infant Nutrition Disorders/epidemiology , Infant Nutrition Disorders/mortality , Infant Nutrition Disorders/prevention & control , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Maternal Health , Morbidity , Pregnancy , Respiratory Tract Diseases/epidemiology , Respiratory Tract Diseases/mortality , South Africa/epidemiology , Sustainable Development , Tuberculosis/epidemiology , Tuberculosis/mortality , Vaccine-Preventable Diseases/epidemiology , Vaccine-Preventable Diseases/mortality , Vaccines/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...